$AVIR
Atea Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022015570 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.38M $12.44M $12.54M
YoY Change -4.72% 4.5% 43.17%
% of Gross Profit
Research & Development $4.905M $19.86M $29.63M
YoY Change -66.18% -50.11% 11.52%
% of Gross Profit
Depreciation & Amortization $106.0K $43.00K $7.000K
YoY Change 1414.29% 186.67%
% of Gross Profit
Operating Expenses $16.28M $32.30M $42.18M
YoY Change -38.43% -37.54% 19.37%
Operating Profit -$16.28M -$32.30M -$42.18M
YoY Change -26.49% -471.76% -237.58%
Interest Expense $4.382M $1.080M $98.00K
YoY Change 8167.92% 1976.92% 63.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$11.90M -$31.22M -$42.08M
YoY Change -46.14% -457.19% -237.0%
Income Tax -$3.833M $120.0K $0.00
% Of Pretax Income
Net Earnings -$8.066M -$31.34M -$42.08M
YoY Change -71.39% -2136.06% -237.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$0.38 -$0.51
Diluted Earnings Per Share -$0.10 -$0.38 -$0.51
COMMON SHARES
Basic Shares Outstanding 83.26M 83.26M 83.18M
Diluted Shares Outstanding 83.26M 83.26M 83.18M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $665.0M $684.5M $705.5M
YoY Change -20.8% -16.16% -15.38%
Cash & Equivalents $176.4M $684.5M $705.5M
Short-Term Investments $488.6M
Other Short-Term Assets $12.45M $4.971M $7.687M
YoY Change 278.76% 6.9% 20.11%
Inventory
Prepaid Expenses
Receivables $4.514M
Other Receivables $0.00
Total Short-Term Assets $681.9M $689.5M $713.2M
YoY Change -19.1% -20.85% -15.1%
LONG-TERM ASSETS
Property, Plant & Equipment $1.810M $1.896M $762.0K
YoY Change 615.42% 481.6% 90.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $305.0K $305.0K $305.0K
YoY Change 0.0% 185.05% 205.0%
Total Long-Term Assets $4.641M $4.887M $3.957M
YoY Change 731.72% 1028.64% 691.4%
TOTAL ASSETS
Total Short-Term Assets $681.9M $689.5M $713.2M
Total Long-Term Assets $4.641M $4.887M $3.957M
Total Assets $686.6M $694.3M $717.2M
YoY Change -18.6% -20.33% -14.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.118M $13.89M $3.657M
YoY Change -94.96% 29.75% -3.76%
Accrued Expenses $13.81M $11.21M $22.38M
YoY Change -61.3% -63.57% 48.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.63M $25.11M $28.61M
YoY Change -94.03% -90.83% -88.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.755M $8.774M $8.695M
YoY Change 30155.17% 7594.69%
Total Long-Term Liabilities $7.755M $8.774M $8.695M
YoY Change 30155.17% 7594.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.63M $25.11M $28.61M
Total Long-Term Liabilities $7.755M $8.774M $8.695M
Total Liabilities $23.39M $33.88M $37.31M
YoY Change -91.07% -87.62% -85.34%
SHAREHOLDERS EQUITY
Retained Earnings -$25.45M -$17.38M $13.95M
YoY Change -58.35% -140.51%
Common Stock $83.00K $83.00K $83.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $663.2M $660.5M $679.9M
YoY Change
Total Liabilities & Shareholders Equity $686.6M $694.3M $717.2M
YoY Change -18.6% -20.33% -14.69%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.066M -$31.34M -$42.08M
YoY Change -71.39% -2136.06% -237.0%
Depreciation, Depletion And Amortization $106.0K $43.00K $7.000K
YoY Change 1414.29% 186.67%
Cash From Operating Activities -$21.24M -$19.19M -$59.01M
YoY Change -193.98% 10.36% 250.47%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$1.879M $44.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$487.0M
YoY Change
Cash From Investing Activities -$487.0M -$1.879M -$44.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 147.0K 0.000 223.0K
YoY Change -81.51% -100.0% -52.65%
NET CHANGE
Cash From Operating Activities -21.24M -19.19M -59.01M
Cash From Investing Activities -487.0M -1.879M -44.00K
Cash From Financing Activities 147.0K 0.000 223.0K
Net Change In Cash -508.1M -21.06M -58.83M
YoY Change -2271.42% 21.36% 259.46%
FREE CASH FLOW
Cash From Operating Activities -$21.24M -$19.19M -$59.01M
Capital Expenditures -$20.00K -$1.879M $44.00K
Free Cash Flow -$21.22M -$17.31M -$59.05M
YoY Change -193.89% -0.45% 250.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
dei Entity Central Index Key
EntityCentralIndexKey
0001593899
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39661
dei Entity Registrant Name
EntityRegistrantName
ATEA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0574869
dei Entity Address Address Line1
EntityAddressAddressLine1
225 Franklin Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2100
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
284-8891
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
AVIR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83258603
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
684480000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
764375000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4971000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8028000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
689451000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
772403000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1896000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
305000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
305000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2686000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
161000
CY2022Q2 us-gaap Assets
Assets
694338000
CY2021Q4 us-gaap Assets
Assets
772892000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
13885000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4534000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
32295000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
51704000
us-gaap Operating Expenses
OperatingExpenses
74470000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
8687000
us-gaap Operating Expenses
OperatingExpenses
87033000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32295000
us-gaap Profit Loss
ProfitLoss
32252000
us-gaap Share Based Compensation
ShareBasedCompensation
23569000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10492000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
52152000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
730000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
25107000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56883000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2766000
CY2022Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
6008000
CY2021Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
5932000
CY2022Q2 us-gaap Liabilities
Liabilities
33881000
CY2021Q4 us-gaap Liabilities
Liabilities
62815000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83257591
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83257591
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83102730
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83102730
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
83000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
83000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
677756000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
653964000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17382000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
56030000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
660457000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
710077000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
694338000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
772892000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60391000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126376000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19858000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39803000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49491000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66375000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12437000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11901000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24979000
us-gaap Net Income Loss
NetIncomeLoss
32252000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20658000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
657921000
us-gaap Net Income Loss
NetIncomeLoss
-73412000
us-gaap Operating Income Loss
OperatingIncomeLoss
-74470000
us-gaap Operating Income Loss
OperatingIncomeLoss
39343000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1080000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
52000
us-gaap Interest And Other Income
InterestAndOtherIncome
1178000
us-gaap Interest And Other Income
InterestAndOtherIncome
109000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31215000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8739000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73292000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
39452000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
120000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
120000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7200000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31335000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1539000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83257591
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82743530
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83217223
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82662019
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83257591
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88091384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83217223
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88683767
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
710077000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
223000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11661000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-42077000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
679884000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11908000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31335000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
660457000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
547801000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
471000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7273000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
30713000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
586258000
CY2022Q2 avir Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Aggregate Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodAggregateGrantDateFairValue
2218000
avir Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Aggregate Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodAggregateGrantDateFairValue
17029000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10007000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1539000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
597861000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1022045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3234295
CY2021Q2 avir Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Aggregate Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodAggregateGrantDateFairValue
19812000
us-gaap Profit Loss
ProfitLoss
-73412000
avir Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Aggregate Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodAggregateGrantDateFairValue
132283000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11908000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10007000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2991000
us-gaap Share Based Compensation
ShareBasedCompensation
17280000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
50000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
15000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
50000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2895000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
293000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9351000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
16456000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-41584000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
23586000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-76376000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
840000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78195000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34185000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1923000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1923000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
223000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
528000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
223000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
528000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-79895000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33657000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
764680000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
850224000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
684785000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
816567000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
684480000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
816460000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
305000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
107000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
684785000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
816567000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2938000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1. Nature of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Background</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Atea Pharmaceuticals, Inc., together with its subsidiary, Atea Pharmaceuticals Securities Corporation, is referred to on a consolidated basis as “the Company”.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from severe viral infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1260416666666666;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company is subject to risks and uncertainties common to clinical-stage biopharmaceutical companies. These risks include, but are not limited to, potential failure of preclinical and clinical studies, uncertainties associated with research and development activities generally, competition from technical innovations of others, dependence upon key personnel, compliance with governmental regulations, the need to obtain marketing approval for any product candidate that the Company may discover and develop, the need to gain broad acceptance among patients, payers and health care providers to successfully commercialize any product for which marketing approval is obtained and the need to secure and maintain adequate intellectual property protection for the Company’s proprietary technology and products. Further, the Company is currently dependent on third-party service providers for much of its preclinical research, clinical development and manufacturing activities. Product candidates currently under development will require significant amounts of additional capital, additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable or be able to sustain profitability. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations. The Company is also subject to risks associated with the COVID-19 global pandemic, including actual and potential delays associated with certain of its ongoing and anticipated trials, and potential negative impacts on the Company’s business operations and its ability to raise additional capital to finance its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company may seek additional capital through one or more of a combination of financing through the sale of additional equity securities, debt financing, or funding in connection with any new collaborative relationships it may enter into or other arrangements. There can be no assurance that the Company will be able to obtain such additional funding, on terms acceptable to the Company, on a timely basis or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing stockholders.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The Company believes that its cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">684,480</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">June 30, 2022 will be sufficient to fund its operations as currently planned through at least twelve months from the issuance of this Quarterly Report on Form 10-Q.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">In November 2021, the Company entered into an open market sales agreement (the “Sales Agreement”) with Jeffries LLC (“Jeffries”), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">200.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million, through or to Jeffries, acting as sales agent or principal. The shares will be offered and sold under the Company’s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the “SEC”) on November 24, 2021, as amended. The Company has agreed to pay Jeffries a commission of up to </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Jeffries with customary indemnification and contribution rights. As of June 30, 2022, </span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> shares have been issued under the Sales Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The COVID-19 pandemic, including the evolution of new and existing variants of COVID-19, and geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia), have resulted in a significant disruption of global financial markets. In addition, market volatility, inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
684480000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23569000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The preparation of unaudited financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include but are not limited to estimates of accrued research and development expenses, valuation of stock-based awards, valuation of operating lease right-of-use assets and lease liabilities and income taxes. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Arial;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Certain items in the prior year’s condensed consolidated financial statements have been reclassified to conform to the current presentation.</span></p>
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
731767000
CY2022Q2 avir Accrued Research And Development Expense Including Manufacturing And Clinical Expenditures Current
AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent
5735000
CY2021Q4 avir Accrued Research And Development Expense Including Manufacturing And Clinical Expenditures Current
AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent
18080000
CY2022Q2 avir Accrued License Fees Current
AccruedLicenseFeesCurrent
0
CY2021Q4 avir Accrued License Fees Current
AccruedLicenseFeesCurrent
25000000
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
15000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2572000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3216000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4209000
CY2022Q2 avir Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
1526000
CY2021Q4 avir Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
2291000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10492000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
52152000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83257591
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83257591
us-gaap Common Stock Voting Rights
CommonStockVotingRights
On all matters to be voted upon by the holders of common stock, holders of common stock are entitled to one vote per share.
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
481584
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3382417
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17280000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11908000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10007000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23569000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17280000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31335000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1539000
us-gaap Net Income Loss
NetIncomeLoss
-73412000
us-gaap Net Income Loss
NetIncomeLoss
32252000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83257591
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82743530
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83217223
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82662019
CY2021Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
5347854
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
6021748
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83257591
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88091384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83217223
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88683767
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
423000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
805000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
821000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
838000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
855000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3742000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
246000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3496000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
730000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2766000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
232000
us-gaap Operating Lease Cost
OperatingLeaseCost
464000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
71000
us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2022Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
120000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
120000
CY2021Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
7200000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
7200000
avir Deferred Tax Assets To Offset Taxable Income
DeferredTaxAssetsToOffsetTaxableIncome
17100000
CY2021Q2 avir Deferred Tax Assets To Offset Taxable Income
DeferredTaxAssetsToOffsetTaxableIncome
17100000
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
126000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
366000
CY2021Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
76000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
76000

Files In Submission

Name View Source Status
0000950170-22-015570-index-headers.html Edgar Link pending
0000950170-22-015570-index.html Edgar Link pending
0000950170-22-015570.txt Edgar Link pending
0000950170-22-015570-xbrl.zip Edgar Link pending
avir-20220630.htm Edgar Link pending
avir-20220630.xsd Edgar Link pending
avir-ex10_1.htm Edgar Link pending
avir-ex10_2.htm Edgar Link pending
avir-ex31_1.htm Edgar Link pending
avir-ex31_2.htm Edgar Link pending
avir-ex32_1.htm Edgar Link pending
avir-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
avir-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
avir-20220630_pre.xml Edgar Link unprocessable
avir-20220630_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
avir-20220630_cal.xml Edgar Link unprocessable
avir-20220630_lab.xml Edgar Link unprocessable